Platinum-resistant Ovarian Cancer Active Not Recruiting Phase 1 Trials for Mirvetuximab soravtansine (DB12489)

Also known as: Platinum drug resistant Ovarian cancer / Platinum-resistant Ovarian Cancer (PROC) / Platinum Resistant Ovarian Cancer

IndicationStatusPhase
DBCOND0068919 (Platinum-resistant Ovarian Cancer)Active Not Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03552471Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal CancerTreatment